Monoclonal antibodies are highly successful therapeutics, but their use can be limited by manufacturing complexity, repeated dosing, and poor tissue penetration. The central nervous system is particularly difficult to reach. Vectorized antibody delivery, or AAV-mediated antibody delivery, uses a viral gene vector to instruct the body’s own cells to produce a therapeutic antibody in vivo. This approach represents a convergence of gene therapy, immunology, protein engineering, synthetic biology, and biologics manufacturing. Vectorized antibody delivery could overcome limitations of traditional antibody treatment.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.